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The recent availability of mice lacking the neuronal form of the
vesicular monoamine transporter 2 (VMAT2) affords the opportu-
nity to study its roles in storage and release. Carbon fiber micro-
electrodes were used to measure individual secretory events of
histamine and 5-hydroxytryptamine (5-HT) from VMAT2-express-
ing mast cells as a model system for quantal release. VMAT2 is
indispensable for monoamine storage because mast cells from
homozygous (VMAT22/2) mice, while undergoing granule-cell fu-
sion, do not release monoamines. Cells from heterozygous animals
(VMAT21/2) secrete lower amounts of monoamine per granule
than cells from wild-type controls. Investigation of corelease of
histamine and 5-HT from granules in VMAT21/2 cells revealed 5-HT
quantal size was reduced more than that of histamine. Thus,
although vesicular transport is the limiting factor determining
quantal size of 5-HT and histamine release, intragranular associa-
tion with the heparin matrix also plays a significant role.
Vesicular monoamine transporters (VMATs) are proteinsthat transport monoamines from the cytoplasm into secre-
tory vesicles (1–3). Along with monoamine synthesis and vesic-
ular storage mechanisms, the transporter plays a central role in
determining the amount of monoamine packaged in a vesicle to
be available for subsequent quantal release by exocytosis (4).
Thus, determining the relative role of these mechanisms is
necessary to understand the regulation of chemical communi-
cation.
To investigate the importance of vesicular transport on mono-
amine release, we examined individual exocytotic release events
of histamine and 5-hydroxytryptamine (5-HT) from mast cells
isolated from VMAT2 knockout mice (5). Genetic deletion of
the gene encoding VMAT2 enabled examination of release from
individual vesicles in which transport was eliminated. Heterozy-
gous (VMAT21/2) mice provided a situation where the number
of transporters expressed was approximately halved, reducing
the capacity for transport in comparison to cells from wild-type
mice. In addition, we have compared results from the heterozy-
gous cells with release from wild-type cells incubated with the
VMAT2 selective inhibitor tetrabenazine (TBZ).
Mast cells have been used successfully as a model system to
study both the role of Ca21 in exocytosis (6) and the regulation
of transmitter release during exocytosis (7). In that work they
allowed analysis of exocytotic release characteristics of two
different monoamines that are stored in the same vesicle but
have different physical chemistries. The vesicular storage of
histamine and 5-HT is promoted by their association with the
highly negatively charged heparin matrix. The matrix in mast cell
secretory granules has properties of a polyanionic hydrogel (8),
and release of monoamines after granule-cell fusion appears to
be driven by a cation-exchange process involving this matrix (9,
10). Because the nature of the association of the two mono-
amines with the heparin proteoglycan is quite different, this
interaction can profoundly affect kinetics and extent of postfu-
sion release (11, 12).
Both histamine and 5-HT are amenable to electrochemical
detection with unparalleled sensitivity and spatio-temporal res-
olution with carbon-fiber microelectrodes (13). Amperometry
and cyclic voltammetry were used in this study along with
microscopic observations to analyze quantal secretion from
individual cells. The hypothesis that VMAT2 expression regu-
lates quantal size (1, 14, 15) was tested for the two costored
monoamines. The results demonstrate the absolute necessity of
the transporter for proper vesicular storage and release and
reveal that vesicular monoamine transport is an important
determinant of quantal size in monoamine-secreting cells.
Materials and Methods
VMAT2 Knockout Mice. VMAT2 knockout mice were generated as
described (5). Briefly, the mouse VMAT2 gene was cloned from
a 129ySvJ library. Appropriate gene fragments were used to
make the knockout construct. After confirming homologous
recombination, positive embryonic stem clones were microin-
jected into C57BLy6 blastocysts and transferred into pseudo-
pregnant mice. After birth, chimeric males showing germ-line
transmission were used to breed with wild-type C57BLy6 fe-
males to generate F1 and F2 mice for experimental analyses.
Individual mouse genotyping was performed by using three PCR
primers andyor a Southern probe.
Mast Cell Preparation. Mast cells were obtained by peritoneal
lavage with 400 ml (1–2 days old) to 5 ml (adult) of pH 7.4
physiological buffer (150 mM NaCly5 mM KCly1.2 mM
MgCl2y5 mM glucosey10 mM Hepesy2 mM CaCl2). Buffer was
retrieved and centrifuged at 200 g to pellet the peritoneal cells.
Cells were resuspended in culture media (DMEMyHam’s F-12,
Life Technologies, Grand Island, NY), plated, and incubated at
37°C before analysis. Mast cells normally comprised 5–10% of
the total number of peritoneal cells and were readily identified
under phase-contrast optics.
VMAT2 Immunofluorescence. Mast cells were obtained as described
above and enriched through antibody-aided flow cytometry.
Cells were resuspended and incubated with FITC-conjugated
anti-B220 mAb and phycoerythrin-conjugated anti-Mac-1 mAb
(Caltag, Burlingame, CA) to label the B cell and macrophage
populations, respectively. After washing, the cells were sorted
through a flow cytometer (FACScan, Becton Dickinson) by
using both color selection and size exclusion. The double-
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negative cells ('10% of the total cells) were collected for
VMAT2 immunofluorescent staining. They were fixed with 3%
paraformaldehyde and incubated with secondary antibody-
matched serum to block nonspecific sites. A primary rabbit
anti-VMAT2 polyclonal antiserum (gift of J. Haycock, Louisiana
State University Medical Center, New Orleans) was applied, and
FITC-conjugated goat-anti-rabbit IgG was used as a secondary
antibody. The cells were stained with toluidine blue to elicit
metachromatic reaction of heparin and viewed with phase-
contrast and fluorescence microscopy.
Carbon Fiber Microelectrodes. Glass-encased carbon fiber disk
microelectrodes were constructed as described (16). Electrodes
were back-filled with a 4 M potassium acetate, 150 mM KCl
solution. Electrodes were calibrated with 5 mM histamine and 1
mM 5-HT.
Single Cell Analysis. A room-temperature culture plate with ad-
hering cells was rinsed and placed in buffer solution. On the
stage of an inverted microscope (Axiovert 35, Zeiss), a piezo-
electric micromanipulator (PCS-1000 Patch Clamp Manipula-
tor, Burleigh Instruments, Fishers, NY) was used to position the
microelectrode adjacent to an isolated mast cell. For amperom-
etry experiments, microelectrodes were placed in direct contact
with the plasma membrane. Microelectrodes were positioned 1
mm away from the cell surface for background-subtracted fast-
scan cyclic voltammetry (FSCV) experiments (13). Release was
induced with 10-sec pressure ejection (8 psi, Picospritzer, Gen-
eral Valve, Fairfield, NJ) of 0.5 mM calcium ionophore A23187
from a 10-mm inner diameter glass micropipette positioned
30–50 mm from the cell (16).
Electrochemistry: FSCV. FSCV measurements were made under
computer control by using a potentiostat (EI-400, Cypress
Systems, Lawrence, KS) in two-electrode mode. To enable
simultaneous histamine and 5-HT detection (16), the electrode
potential was scanned from a rest potential of 1100 mV to
11,400 mV and back to 1100 mV at 800 Vys (potentials
referenced to sodium-saturated calomel electrode) and at a
repetition rate of 30 Hz. Programs for data acquisition (17) were
written in LABVIEW (National Instruments, Austin, TX). For
FSCV spike detection and parameter analysis, locally written
software was used to evaluate in parallel the current-time traces
obtained by averaging data in the 100-mV window centered on
peak oxidation potentials for histamine and 5-HT. Spike maxi-
mal amplitudes were converted to units of maximal concentra-
tion (Cmax) based on postexperiment electrode calibrations.
FSCV experiments and electrode calibrations were performed in
a pH 7.4 Tris buffer (12.5 mM TriszHCly150 mM NaCly4.2 mM
KCly1.4 mM MgCl2y5.6 mM glucosey1.5 mM CaCl2; ref. 16).
Electrochemistry: Constant Potential Amperometry. For amperom-
etry measurements, a patch-clamp instrument (Axopatch 200B,
Axon Instruments, Foster City, CA) was used in voltage clamp
mode. At a potential of 1650 mV versus sodium-saturated
calomel electrode, microelectrode current was monitored (10-
kHz low-pass filter) and digitized to videotape (PCM-2 AyD
VCR Adaptor, Medical Systems, Greenvale, NY). At 1650 mV,
5-HT is oxidized at the electrode but histamine is not. Amper-
ometry experiments were performed in the Hepes buffer used
for cell isolation.
Optical Imaging of Exocytosis. In some experiments, visualization
of exocytosis was enhanced with 50 mgyml ruthenium red, which
avidly binds to heparin (18). Individual mast cells were stimu-
lated via pressure ejection of A23187 and monitored through the
microscope with a charge-coupled device camera. Ruthenium
red was found to partition into mast cell heparin exposed to the
cell surface after granule-cell fusion, enabling visualization of
the exocytotic process in real time.
Reagents and Solutions. Histamine dihydrochloride, 5-HT hydro-
chloride, epinephrine (free base), toluidine blue, ruthenium red,
and calcium ionophore A23187 were obtained from Sigma. TBZ
was obtained from Fluka. All other compounds were obtained
from Sigma and used as received, unless otherwise noted.
A23187 stimulating solution was prepared by 1,000-fold dilution
in physiological buffer of a stock solution in DMSO. Histamine
and 5-HT solutions for electrode calibration were prepared by
dilution in buffer of stock solutions in 0.1 M HClO4. Solutions
were prepared in doubly distilled deionized water and adjusted
to pH 7.4 by addition of NaOH or HCl.
Results
Presence of VMAT2 in Murine Mast Cells. Immunofluorescence was
used to check for expression of VMAT2 in mouse peritoneal
mast cells, which were purified by using antibody-aided flow
cytometry. Identity of mast cells was confirmed by metachro-
matic staining of heparin with toluidine blue. Cells that stained
positive with toluidine blue concurrently displayed VMAT2
immunofluorescence (see Fig. 6, which is published as supple-
mentary material on the PNAS web site, www.pnas.org). Thus,
VMAT2 expression is confirmed in the cells used for studies of
exocytosis.
Absence of Monoamine Quantal Release from VMAT22/2 Mast Cells.
To investigate the effects of VMAT2 absence on monoamine
release, mast cells were obtained from newborn homozygous
mice (VMAT22/2) as well as VMAT21/2 and wild-type
(VMAT21/1) littermates. Newborn mast cells were approxi-
mately 8 mm in diameter, compared with the 10- to 12-mm
diameter adult mast cells. With the microelectrode potential at
1650 mV, amperometry allows temporally resolved measure-
ment of quantal release of 5-HT without detection of histamine
(16). Cells from VMAT21/1 and VMAT21/2 newborn mice
exhibited 5-HT secretion when exposed to the calcium iono-
phore A23187 (Fig. 1). In contrast, none of the 53 stimulated
cells examined from seven VMAT22/2 pups showed any current
transients. Cyclic voltammetry was used to confirm that hista-
mine also is released from wild-type and VMAT21/2 cells from
pups, but not VMAT22/2 cells (see Fig. 7, which is published as
supplementary material on the PNAS web site).
Visual Observation of Granule-Cell Fusion in VMAT22/2 Mast Cells.
Visual monitoring of mast cell degranulation was used to
evaluate the exocytotic competency of cells from newborn
VMAT22/2 mice. Because of the relatively large size of mast cell
secretory granules (0.7 mm mean diameter in adult cells), the
morphological changes that occur at the cell membrane because
of granule-cell fusion can be observed microscopically. Mast
cells of all genotypes exhibited clear degranulation upon stim-
ulation with A23187 in the presence of Ca21. Because mast cells
from newborns are somewhat smaller and have less robust
release characteristics compared with their adult counterparts,
ruthenium red staining was used to enhance visualization of
exocytosis (18). Pressure ejection of A23187 onto the cell evokes
exocytosis that is observed as a progressive increase in cell
surface staining caused by incorporation of the cationic red dye
into discrete areas where polyanionic heparin is exposed to the
outer surface by granular fusion (Fig. 2). The appearance of red
punctate staining indicated a rapid succession of individual
granule fusion events distributed over the entire cell surface,
leading to a general disruption of the previously well-defined cell
membrane. By this method, exocytosis was observed to occur in
mast cells from newborns for all genotypes, including
VMAT22/2 cells.













Histamine and 5-HT Release from VMAT21/2 Mast Cells. The three-
dimensional false-color plot in Fig. 3 shows a 20-sec segment of
background-subtracted FSCV data obtained at an adult
VMAT21/2 mast cell stimulated with A23187. The color plot
(19) represents all of the current data as a function of electrode
potential obtained during a series of repeated potential scans. As
shown in the two-dimensional cyclic voltammogram (top of Fig.
3) taken from one of the transient current features in the data,
each voltage scan (3.25 ms in duration) provides information on
electroactive species present at the electrode surface. The vol-
tammetric peak that occurs around 1550 mV on the forward
scan corresponds to 5-HT oxidation. The oxidative peak that
occurs around 11,300 mV is caused by histamine. The additional
peak often seen on the forward scan is a time-dependent wave
resulting from a histamine product generated by prior voltage
scans (16). If the voltammetric current is sampled on successive
scans and averaged in the 100-mV peak oxidation potential
window for histamine, a current trace is obtained that tracks
changes in histamine concentration (Fig. 3, upper trace). Simi-
larly, a plot that follows 5-HT concentration changes may be
constructed by averaging the current in the 100-mV oxidation
potential window for 5-HT (Fig. 3, lower trace).
The representative VMAT21/2 cell in Fig. 3 exhibits corelease
of histamine and 5-HT in response to stimulation. Similar data
were obtained at VMAT21/1 cells. However, release concen-
trations differed between VMAT21/1 and VMAT21/2 cells. On
average, VMAT21/2 cells exhibited histamine spike amplitudes
(Cmaxs) that were 32% smaller and 5-HT spike amplitudes that
were 57% smaller than those of the wild-type littermates (Fig.
4A). For some histamine spikes, corresponding 5-HT spikes were
absent or lost in baseline noise. The time course of each release
event was not significantly altered by VMAT2 expression as
indicated by similar spike widths. For each temporally correlated
secretion event, the resulting ratio of histamine to 5-HT for
VMAT21/2 spikes was approximately double that of VMAT21/1
spikes (Fig. 4A). This difference in secreted amounts is also
apparent in Fig. 4B where histamine Cmax and 5-HT Cmax are
plotted for each secretion event and grouped by genotype.
Though the scatterplots reveal that Cmax ratios are heteroge-
neous, a linear correlation exists. The 2-fold difference in
regression line slope between the two genotypes also reflects the
difference in histaminey5-HT ratio.
At mast cells from both genotypes, some exocytotic events
exhibit a small amplitude feature that precedes the main body of
the concentration spike. This prespike feature, or ‘‘foot,’’ is
believed to correspond to detection of the flux of transmitter
molecules through a fusion pore before complete expansion and
release of vesicle content (20, 21). Well-resolved FSCV record-
ings of release during the foot (example shown in Fig. 5) show
simultaneous histamine and 5-HT appearance. A cyclic volta-
mmogram obtained during the spike phase further demonstrates
that the species detected during the foot and spike are identical.
Effects of Long-Term Incubation with TBZ on Histamine and 5-HT
Release. Monoamine release from mast cells of wild-type adult
animals also was examined after incubation with TBZ, a VMAT2
selective inhibitor. No effects were seen on exocytotic release
with incubations up to 1 hr with 10 mM TBZ. However, 24-hr
Fig. 1. Amperometric measurement of exocytosis from newborn VMAT21/1,
VMAT21/2, and VMAT22/2 mast cells. Traces show secretory responses of
calcium ionophore A23187-stimulated cells representative of each genotype
as measured by amperometry (1650 mV vs. sodium-saturated calomel elec-
trode).
Fig. 2. Bright-field photomicrographs show degranulation of mouse peri-
toneal mast cell with visual enhancement by ruthenium red staining. A
VMAT21/1 mast cell in 50 mg/ml of ruthenium red solution is shown before (A)
and 5 min after (B) pressure ejection of A23187 solution onto the cell from a
nearby stimulating pipette. Morphological changes in cell border and staining
of heparin from individual fused granules clearly demonstrate exocytosis has
occurred.
Fig. 3. FSCV measurement of cosecretion of histamine and 5-HT from
A23187-stimulated VMAT21/2 mast cell. The upper (HIS) trace shows changes
in histamine concentration over the 20-s interval by sampling current at
11,300 mV (reverse scan) on successive scans. The lower (5-HT) trace shows
changes in 5-HT concentration obtained by sampling current at 1550 mV vs.
sodium-saturated calomel electrode (forward scan) on successive scans. The
inset plot shows a single cyclic voltammogram taken at the peak time of the
circled spike.
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incubation with 10 mM TBZ profoundly affected the amplitude
of individual 5-HT secretory spikes measured by cyclic voltam-
metry (Fig. 4C). The average 5-HT concentration spike ampli-
tude (Cmax) for TBZ-treated cells was 51% of average 5-HT Cmax
for control cells of the same animals. Average histamine Cmax, on
the other hand, was found to be nearly 33% greater than control.
For temporally matched histamine and 5-HT spikes, the hista-
mine to 5-HT Cmax ratio was 7.5 for control cells and 28.6 for
TBZ-treated cells. Thus, pharmacological inhibition of VMAT2
also causes a dramatic increase in the histaminey5-HT ratio.
Discussion
The results of this study at the level of individual release events
provide confirmation that VMAT2 is essential for granular
monoamine accumulation and, thus, its subsequent release.
Although VMAT22/2 mice only survive a few days, mast cells
could be obtained from newborn animals and their wild-type and
VMAT21/2 littermates, enabling their release characteristics to
be compared. The electrochemical techniques allowed simulta-
neous measurement of 5-HT and histamine secretion. The
temporal correspondence of monoamine concentration spikes
during exocytosis from cells isolated from VMAT21/1 and
VMAT21/2 mice indicates that histamine and 5-HT are core-
leased from the same secretory granule as shown previously in
rat peritoneal mast cells (16). The two monoamines also were
found to be coreleased during the initial formation of the fusion
pore that precedes the primary secretory events from both
VMAT21/1 and VMAT21/2 mast cells. In dramatic contrast,
mast cells without VMAT2 do not release either amine during
exocytosis. Exocytosis at mast cells from all three types of mice
was readily visualized in the presence of ruthenium red because
of its accumulation in polyanionic heparin accumulated on the
cell surface.
Two subtypes of monoamine transporter (VMAT1 and
VMAT2) have been cloned and characterized (22–25). The
mutant mice used in this work lack the neuronal isoform
VMAT2 (5, 15, 26). VMAT21/2 mice exhibit reduced levels of
brain monoamines whereas VMAT22/2 mice are almost com-
pletely devoid of brain monoamines (5, 15). Depolarization
induced monoamine release from brain measured in vivo or from
cell cultures is eliminated in the homozygous animals. Release
from cultured VMAT21/2 neurons is half of that found in
VMAT21/1 cells (15). This work provides additional informa-
tion in that it allows an assessment at the level of individual
excocytotic events as to how alterations in VMAT2 expression
affect monoamine release. VMAT2 has been postulated to be
the isoform in mast cells (27, 28) because the affinity of VMAT2
for histamine (KM 5 3.06 mM) is much higher than that of
VMAT1 (KM 5 436 mM) (29). Our immunocytochemical result
confirms this hypothesis. The absence of either histamine or
5-HT release from VMAT22/2 cells shows that other transport-
ers, including VMAT1, are unable to replace, in the homozygous
animals, the role normally played by VMAT2.
Fig. 4. Analysis of histamine and 5-HT concentration spike amplitudes
observed by cyclic voltammetry during exocytosis at mast cells. (A) Effects of
reduced VMAT2 expression on histamine and 5-HT FSCV spike amplitudes.
(Left) A comparison of mean histamine and 5-HT spikes (Cmax)for secretion
measured from VMAT21/1 (n 5 13 cells of two mice) and VMAT21/2 (n 5 12
cells of two mice) mast cells. Data are expressed as percent of wild-type
response with the dashed line showing 100%. (Right) The mean ratio of
histamine to 5-HT for simultaneously occurring spikes from the two geno-
types. (B) Scatterplots of 5-HT Cmax versus histamine Cmax for temporally
coincident secretory spikes measured at VMAT21/1 and VMAT21/2 mast cells.
For VMAT21/1 cells (401 spikes from 13 cells of two mice), linear regression line
has slope of 0.06 and correlation coefficient of 0.94. For VMAT21/2 data (285
spikes from 12 cells of two mice), the slope is 0.03 and correlation coefficient
is 0.77. (C) Effects of inhibition of VMAT2 on histamine and 5-HT FSCV spike
amplitudes. (Left) A comparison of mean histamine and 5-HT spike Cmax for
secretion from VMAT21/1 mast cells, both untreated (con, n 5 10) and incu-
bated with 10 mM TBZ for 24 hr (n 5 11). Data are expressed as percent of
control response with dashed lines showing 100%. (Right) Mean ratio of
histamine Cmax to 5-HT Cmax for simultaneously occurring spikes of control and
TBZ-treated cells. Error bars are SEM. The number of spikes detected and
analyzed under each condition is shown on the bar.
Fig. 5. FSCV detection of histamine and 5-HT released through fusion pore
of VMAT21/1 mast cell. Electrochemical current sampled at peak oxidation
potentials for both histamine (Upper Left) and 5-HT (Lower Left) during an
individual exocytotic event exhibit the presence of a foot. Concentrations
measured at the electrode during the foot were 0.03 and 0.31 mM for 5-HT and
histamine, respectively. In contrast, the spike peak concentrations were 0.48
and 4.38 for 5-HT and histamine, respectively. (Right) Cyclic voltammograms
obtained during the foot and at the spike maximum are shown. Their simi-
larity clearly shows that the same species are released during the two phases
of exocytosis.













Previously, it has been hypothesized that VMATs could
influence quantal release by a change in quantal size or a change
in quantal number (1, 14). VMAT2 control over quantal size
implies that kinetics of monoamine transport into the vesicle
determine the amount available for release. A change in quantal
number would imply VMAT2 involvement in regulation of
vesicle biogenesis or recruitment. The present work establishes
that VMAT2 expression exerts its principal influence on quantal
size. Conversely, overexpression of VMAT2 (15) or the vesicular
acetylcholine transporter (30) both result in several-fold in-
creases in quantal size. However, quantitative examination of the
results from VMAT21/1 and VMAT21/2 mast cells from adult
animals reveals that storage of 5-HT and histamine is regulated
differentially. 5-HT released from VMAT21/2 mast cell granules
is 43% of that from wild-type cells whereas histamine released
from VMAT21/2 cells is 68% of that from wild-type cells. Thus,
in addition to VMAT2, other factors must play an important role
in regulating monoamine storage.
In the heterozygous animal, differences in substrate availabil-
ity could be the origin of the observed difference in relative
secretion. Indeed, because histamine can inhibit 5-HT uptake
(27), an excess of this amine would lead to a decrease in released
5-HT. Another factor affecting storage of both monoamines in
mast cell granules is the association of histamine and 5-HT with
the granular matrix comprised of negatively charged heparin and
basic protein. The granular association is quite strong, leading to
a half-life of histamine in mast cells of greater than 20 days (31).
During exocytosis, the matrix dissociates upon encountering the
higher pH and lower osmolarity of the extracellular fluid (32).
Histamine is more strongly associated with the heparin matrix
(33) because, at the intragranular pH of 5.8 (34), about half of
the histamine is diprotonated (pKa2 5 5.9) whereas the majority
of the 5-HT is monoprotonated (pKa2 5 4.9). Prior studies of
quantal release from mast cells have revealed that this differ-
ential association of histamine and 5-HT with the granule ma-
trix profoundly affects the kinetics and extent of exocytotic
release (12).
A mechanism that accounts for VMAT2 transport, storage
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VMAT2 is responsible for transporting cytoplasmic monoamine
(MAcyt) to the vesicle interior whereas a leakage mechanism
(leak) contributes to its return to the cytoplasm (4). Normally,
the soluble portion of monoamine in the vesicle (MAves) exists
in an equilibrium (defined by Kasn) with monoamine that is
bound to the granule matrix (MAbound). When exocytosis occurs,
MAves can leave the granule and the carbon-fiber microelectrode
detects it in the extracellular fluid (MAecf). Thus, MAves is the
source of the ‘‘foot’’ events that occur immediately upon for-
mation of the fusion pore (20). Pore formation is followed by
granular swelling that decreases Kasn, increasing MAves and
leading to the concentration spikes observed electrochemically.
As a result of the stronger association of histamine with the
matrix when compared with 5-HT, the relative amount of
releasable histamine under storage conditions is less than that of
5-HT. Thus, even though they are in the same granule, 5-HT has
more opportunity to leak into the cytoplasm, which places a
stronger demand on VMAT2 to maintain its stored amount. The
net result is that 5-HT quantal size will be more sensitive to
functional VMAT2 levels than histamine.
To test this scheme under conditions where substrate avail-
ability should not be an issue, VMAT2 in mast cells from
wild-type mice was pharmacologically inhibited. Prolonged in-
cubation with TBZ was required for a measurable effect, indi-
cating that, in spite of the weaker association of 5-HT with the
intragranular matrix, matrix dissociation kinetics and leakage are
quite slow in the granule during storage. In contrast, the egress
of monoamines from small, clear neuronal vesicles, where in-
travesicular association is less likely, occurs in a few minutes after
VMAT2 inhibition (35). However, similar to the effects of
reduction in VMAT2 expression on mast cell storage, inhibition
of the transporter leads to differential changes in granular
monoamine release. In this case, only the amount of 5-HT
release was diminished whereas histamine spike amplitude
actually increased. Because substrates were not added and the
content could not change, the only mechanism whereby this
effect could arise would be from 5-HT granular leakage during
TBZ incubation causing a change in Kasn, thus allowing more
bound histamine to become soluble in the vesicle. Indeed,
granule swelling indicative of reduced association is observed
upon egress of 5-HT from the granule (10). 5-HT release could
be further modulated by the increased cytoplasmic histamine
because it also can inhibit VMAT2-mediated 5-HT transport
(25). Thus, with both reduced VMAT2 number and its pharma-
cological inhibition, we find that 5-HT is depleted to a greater
degree than histamine.
The present results show that differential regulation of chem-
ical messenger storage in the same vesicle can occur if a strongly
associating matrix is present, a fact not previously appreciated.
Therefore, in addition to the fundamental importance of
VMAT2 transport, polyanionic storage matrices that promote
intravesicular storage also play an important role in maintaining
chemical levels in vesicles and the amount released during
chemical communication. These findings have direct relevance
for neurotransmitters stored in dense core vesicles where pro-
tein-small molecule association also can occur. However, as
shown in this work, even when intravesicular association pro-
motes storage, VMATs are essential for transport of mono-
amines into their storage location. Because the monoamines
transported by VMAT2 in neurons regulate mood and emotion,
alterations in functional VMAT2 could have significant behav-
ioral effects by modulation of neuronal communication.
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